FDA Approves Gamida Cell’s Cell Therapy for Treating Blood Cancers
Gamida Cell’s therapy is meant to reduce the risk of infection following stem cell transplantation.
FDA announced on April 17, 2023 the approval of Israel-based cell therapy company Gamida Cell’s Omisirge (omidubicel-onlv), a substantially modified allogeneic cord blood-based cell therapy to quicken the recovery of neutrophils, a subset of white blood cells, in the body and reduce the risk of infection.
The therapy is intended for use in adults and pediatric patients aged 12 years and older with blood cancers planned for umbilical cord blood transplantation following a myeloablative conditioning regimen, such as radiation or chemotherapy. Gamida Cell will manufacture Omisirge at its good manufacturing practice facility in Kiryat Gat, Israel. The company expects to deliver the cell therapy to transplant centers within 30 days after the start of manufacturing.
Stem cell transplantation is a common treatment for blood cancers. The procedure involves insertion of healthy stem cells in the body to help restore normal production and function of blood cells. Generally, a patient will undergo therapies such as radiation or chemotherapy before this kind of transplant, which may weaken an individual’s immune system. As a result, a frequent and serious risk of this treatment is the occurrence of severe and sometimes deadly infections.
“Today’s approval is an important advance in cell therapy treatment in patients with blood cancers,” said Peter Marks, director of the FDA’s Center for Biologics Evaluation and Research, in an FDA press release. “Hastening the return of the body’s white blood cells can reduce the possibility of serious or overwhelming infection associated with stem cell transplantation. This approval reflects [FDA]’s continued commitment to supporting development of innovative therapies for life-threatening cancers.”
Source: FDA and Gamida Cell
Trump Directs FDA, EPA to Reduce Regulatory Barriers to Domestic Pharma Manufacturing
May 7th 2025The White House is instructing FDA to increase fees for and inspections of foreign drug manufacturing plants and reduce the time required to approve such sites that will be newly constructed in the US.
New Cancer Research and Treatment Center in Development in London
May 1st 2025Aviva Capital Partners and developer Socius are investing £1 billion in a 12-acre site to be located at the London Cancer Hub next to The Institute of Cancer Research, London and The Royal Marsden NHS Foundation Trust’s Sutton site.
Regeneron Treatment for Multiple Myeloma Gets Conditional Marketing Approval from EC
April 29th 2025The indication is specific to patients who have received at least three prior therapies, including a proteasome inhibitor, immunomodulatory agent, and anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy.
